Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
Riccardo Menandro, Pharmaceutical Scientific Reporter at Maven Pharma, shared on LinkedIn:
”Most conversations about lipid nanoparticles focus on the science.
This one focuses on the decisions.
LNP technology has moved from research platform to clinical mainstream faster than almost any other delivery system in recent memory.
Patisiran demonstrated hepatic gene silencing at therapeutic scale.
The COVID-19 vaccines demonstrated industrial scalability.
The pipeline now spans oncology, rare disease, hemophilia, and in vivo CRISPR editing.
But for organizations building or evaluating LNP-based programs, the scientific opportunity is only part of the picture.
Formulation expertise, IP position, tissue targeting strategy, and regulatory engagement are the variables that determine whether a program reaches the clinic on a competitive timeline, or doesn’t.
This white paper examines all four, with a focus on the decisions that matter most at the development planning stage.
Full document attached.”
Stay updated with Hemostasis Today.
-
Jul 18, 2026, 12:17Doruntina Lahu: Prasugrel and Ticagrelor – Does Sex Matter?
-
Jul 18, 2026, 11:54Paul Riley: Presenting STAR Max3 at ISTH 2026
-
Jul 18, 2026, 11:38Abdul Mannan: Normal Blood DEB Test Does Not Always Rule Out Fanconi Anaemia
-
Jul 18, 2026, 10:47Adela Perolla: Lighting the Flame for Future Hematologists
-
Jul 18, 2026, 10:29Ekaterina Balaian: The 100-Year Story of VWD
-
Jul 18, 2026, 08:56Cancer-Associated Arterial Thromboembolism: The Overlooked Cardiovascular Threat in Oncology
-
Jul 17, 2026, 23:05Leonardo Roever: New Perspectives on Thromboinflammation in Acute Ischemic Stroke
-
Jul 17, 2026, 22:36Maeva May: Start Your Stroke Research Career with a Stroke Association Fellowship
-
Jul 17, 2026, 20:19Thomas Muenzel: Proud to Deliver the Sylviane Lévy-Toledano Memorial Plenary Keynote Lecture at ISTH 2026